Lucid Diagnostics Inc. cash flow to debt ratio of -180.03% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lucid Diagnostics Inc.'s free cash flow has decreased 3.79% from $-44.79M last year to $-46.48M, signaling decreasing performance

Lucid Diagnostics Inc.'s debt to equity ratio is 6.70, which means that the company's assets are unhealthy financed, signaling financial risk.

Lucid Diagnostics Inc.'s debt has increased relative to shareholder equity from 3.94 last year to 6.70 today, signaling weakened financials

Lucid Diagnostics Inc. has a net cash position, so leverage is healthy.

Lucid Diagnostics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Lucid Diagnostics Inc.'s profit margin has increased (-16.31%) in the last year from -1.05K% to -876.72%, signaling increasing performance

Lucid Diagnostics Inc.'s short-term assets of $37.47M exceed its short-term liabilities of $28.58M

Lucid Diagnostics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lucid Diagnostics Inc.'s return on equity of -370.21%, is lower than 15.00%, indicating bad performance

Lucid Diagnostics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lucid Diagnostics Inc. has insufficient public price history to evaluate earnings stability.

Lucid Diagnostics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lucid Diagnostics Inc. has negative free cash flow, indicating cash burn

Lucid Diagnostics Inc.'s yearly earnings has decreased 27.41% since last year from $-45.53M to $-58.01M, signaling decreasing performance

Lucid Diagnostics Inc.'s yearly revenue has increased 108.18K% since last year from $4.35M to $4.71B, signaling increasing performance

ROIC -159.95% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lucid Diagnostics Inc.'s 3-year revenue CAGR of 131.97% is positive, indicating growing revenue over the past 3 years

Lucid Diagnostics Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Lucid Diagnostics Inc. has insufficient public price history to evaluate ROE consistency.

Lucid Diagnostics Inc. is undervalued relative to its fair value price of 6.43 based on Discounted Cash Flow model

Lucid Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lucid Diagnostics Inc. is undervalued relative to its fair value price of 83.52 based on EBITDA multiple model

Lucid Diagnostics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lucid Diagnostics Inc. has insufficient data to evaluate this check.

Lucid Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lucid Diagnostics Inc. has a price-to-book ratio of 24.52x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Lucid Diagnostics Inc. has a price-to-sales ratio of 19.07x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue